Elsevier

Nutrition

Volume 31, Issue 1, January 2015, Pages 72-78
Nutrition

Applied nutritional investigation
Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure

https://doi.org/10.1016/j.nut.2014.04.021Get rights and content

Abstract

Objective

Chronic heart failure (CHF) is characterized by several micronutrient deficits. Amino acid supplementation may have a positive effect on nutritional and metabolic status in patients with CHF. Levo-carnosine (β-alanyl-l-histidine) is expressed at a high concentration in myocardium and muscle. Preliminary studies with l-carnosine in healthy individuals have suggested a potential role in improving exercise performance. To our knowledge, no study has been conducted in patients with heart failure. The aim of this study was to test the oral supplementation of l-carnosine and its effects on quality of life and exercise performance in patients with stable CHF.

Methods

Fifty patients with stable CHF and severe left-ventricular systolic dysfunction on optimal medical therapy were randomized 1:1 to receive oral orodispersible l-carnosine (500 mg OD) or standard treatment. Left-ventricular ejection fraction (LVEF) was measured by echocardiography. Cardiopulmonary stress test, 6-minute walking test (6MWT) and quality-of-life (visual analog scale score and the EuroQOL five dimensions questionnaire [EQ-5D]) were performed at baseline and after 6 mo.

Results

Patients receiving orodispersible l-carnosine had an improvement in 6MWT distance (P = 0.014) and in quality-of-life (VAS score) (P = 0.039) between baseline and follow-up. Compared with controls, diet supplementation with orodispersible l-carnosine was associated with an improvement in peakVO2 (P < 0.0001), VO2 at anaerobic threshold, peak exercise workload, 6MWT and quality-of-life assessed by the EQ-5D test and the VAS score.

Conclusion

This study suggests that l-carnosine, added to conventional therapy, has beneficial effects on exercise performance and quality of life in stable CHF. More data are necessary to evaluate its effects on left-ventricular ejection fraction and prognosis in CHF.

Introduction

Heart failure (HF) is characterized by a poor quality of life (QoL), adverse prognosis, and high medical costs. [1] Despite advances in drug therapy and development of new devices to improve patient prognosis, individuals with chronic heart failure (CHF) continue to have an unsatisfactory QoL and reduced exercise tolerance. A hallmark of HF is the reduced ability to perform aerobic exercise. This reduction in functional capacity and exercise tolerance is mediated by several factors including alterations of endothelial and vasodilatory function, abnormalities in skeletal muscle metabolism, and reduction in muscle blood flow during exercise [2]. Improving these parameters remains a major unmet need of HF treatment. Recently, the role of the nutritional status and cachexia in HF has been extensively shown [3], [4], [5]. Supplementation of essential amino acids (AAs) has demonstrated promising results with regard to improvement of functional capacity and, in some cases, in left ventricular ejection fraction (LVEF) [6], [7], [8]. Although these studies were small in size and heterogeneous with regard to the analyzed molecules, they highlight the need for a deeper knowledge of the effects of nutritional support and the correction of macro- and micronutrient deficiencies in patients with HF. The failing heart is exposed to several mechanisms (hemodynamic, neurohormonal, and inflammatory) that contribute to left-ventricular remodeling and to progressive decrease in cardiac function [9]. Recently, it has been proposed that one mechanism of action of these stressors may involve myocytes metabolism (metabolic remodeling) in the failing heart, where AAs become essential for energy production through the Krebs cycle [10], [11]. AAs also regulate protein turnover and synthesis, and contribute to the maintenance of hormonal balance by increasing the activity of anabolic hormones. An adequate intake of AAs, therefore, may be of primary importance in patients with HF and AA supplementation may represent a proper treatment, by reverting the alterations of cardiac and systemic metabolism [12].

Levo-carnosine (l-carnosine) is a cytoplasmic dipeptide (β-alanyl-l-histidine) found in high concentrations in the tissues of longeval mammals, especially in muscles, heart, and brain [13], [14], [15]. In vitro studies have shown the ability of carnosine to slow the aging of human fibroblasts [16], [17]. Other studies also have demonstrated that the levels of carnosine decrease with age, with a loss of 63%, from 10 to 70 y and carnosine levels in mammals also seem to be directly correlated with life expectancy [18]. Carnosine is considered a multifunctional molecule with antioxidant and antiaging action, and operates as a selective inhibitor of protein glycosylation and protein–protein cross-linking [19], [20], [21], [22]. In humans, the carnosinase enzyme degrades circulating carnosine. Recent studies have shown that the diabetic nephropathy is associated with a (CTG)n polymorphism in the carnosine dipeptidase-1 gene (CNDP1), and patients homozygous for (CTG)5 have a lower risk for developing diabetic nephropathy and also have lower plasma levels of carnosinase [23]. Studies included small groups of patients have demonstrated that oral supplementation of carnosine in subjects with deficient carnosinase enzyme activity increases carnosinemia and could have a protective effect on the kidneys of patients with diabetes by reducing glycation end products and oxidative stress [24], [25]. Recently, the administration of carnosine has been associated with a nephroprotective effect in patients with diabetic nephropathy, and nephropathy induced by contrast medium. This favorable effect seems to be related to the reduction of plasma levels of proinflammatory cytokines and the synthesis of fibronectin and type IV collagen [26]. In preliminary studies, carnosine has been shown to induce Na,K-ATPase activation and to prevent membrane depolarization with a potential role in the management of HF and myocardial infarction [27]. In a rabbit model in which HF was induced by infusing doxorubicin, the administration of carnosine reduced cardiotoxic effects compared with rabbits treated with doxorubucine alone [28]. Carnosine plays a key role against the oxidative damage that occurs during exercise under anaerobic conditions. During exercise, there is an increase of lactic acid with a subsequent dissociation into lactate and H+, which reduce pH levels. These protons are usually buffered by the bicarbonate system, which has an acid dissociation constant (pKa) of 6.1, whereas l-carnosine has a pKa value of 6.83, closer to the physiological pH (7.38–7.42) [29]. Carnosine plays an effective buffering action through the imidazole group of histidine, which binds a proton reducing the pH value. The pKa of carnosine is closer to the physiological pH and could be used sooner as a buffer during exercise [30], [31]. An increase in muscle l-carnosine levels may improve contractility and reduce fatigue [32]. Other mechanisms include regulatory effects on myocardial calcium levels, an increase in sensitivity of calcium-release channels and of the contractile apparatus, with favorable effects on cardiac contractility and function [33], [34], [35]. Thus, carnosine is potentially useful as an addition to the standard treatment of patients with HF. The aim of this study was to test the oral supplementation of l-carnosine and its effects on QoL and exercise performance in patients with stable CHF.

Section snippets

Study patients

We studied patients with HF of ≥6-mo duration, with New York Heart Association (NYHA) class II or III symptoms, an LVEF ≤45% by echocardiography and the ability to perform a cardiopulmonary exercise test. Patients had to be on optimal medical therapy, including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and β-blockers, if not contraindicated, at stable dose for at least 4 wk before entering the study. Patients were excluded if they had symptoms of myocardial

Results

The study group included 50 consecutive ambulatory patients (mean age, 62.01 ± 9.55 y) with CHF due to left-ventricular systolic dysfunction (mean LVEF, 33.21 ± 7.57), who were referred to our institute between June and November 2012 and randomized to receive l-carnosine (500 mg OD) on top of standard therapy or standard treatment.

At study entry, the two groups were balanced with respect to demographic, clinical, and biochemical variables, as well as medical therapy (Table 1).

All patients were

Discussion

To our knowledge, this study is the first to analyze the effects of oral supplementation in a 500 mg/d dose of l-carnosine in ambulatory patients with HF and severe left-ventricular systolic dysfunction, focusing on the effect on exercise tolerance and QoL. The administration of l-carnosine was performed in patients on optimized therapy for HF and who were clinically stable. l-carnosine is a dietary supplement in the formulation of orodispersible tablet. Carnosine is a molecule composed of two

Conclusion

This investigation demonstrated that once-daily oral supplementation of 500 mg l-carnosine, added to conventional therapy, may improve exercise performance and QoL in ambulatory patients with stable CHF. This study did not test l-carnosine against placebo and enrolled a relatively small number of patients. More data are necessary to confirm these promising results and placebo-controlled studies enrolling a larger number of patients are needed to evaluate potential effects of l-carnosine on

References (56)

  • I.L. Piña et al.

    Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention

    Circulation

    (2003)
  • E. Pasini et al.

    Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach

    Ital Heart J

    (2003)
  • R. Aquilani et al.

    Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure

    Am J Cardiol

    (2008)
  • J.J. Orozco-Gutiérrez et al.

    Effect of L-arginine or L-citrulline oral supplementation on blood pressure and right ventricular function in heart failure patients with preserved ejection fraction

    Cardiol J

    (2010)
  • K.K. Witte et al.

    The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure

    Eur Heart J

    (2005)
  • S. Neubauer

    The failing heart—an engine out of fuel

    N Engl J Med

    (2007)
  • J.S. Ingwall

    On the hypothesis that the failing heart is energy starved: lessons learned from the metabolism of ATP and creatine

    Curr Hypertens Rep

    (2006)
  • H. Tuunanen et al.

    Myocardial fatty acid metabolism and cardiac performance in heart failure

    Curr Cardiol Rep

    (2008)
  • H. Taegtmeyer et al.

    More than bricks and mortar: comments on protein and amino acid metabolism in the heart

    Am J Cardiol

    (2008)
  • H.J. Stuenenburg et al.

    Concentration of free carnosine (a putative membrane-protective antioxidant) in human muscle biopsies and rat muscles

    Arch Gerontol Geriatrics

    (1999)
  • R. Kohen et al.

    Antioxidant activity of carnosine, homocarnosine and anserine present in muscle and brain

    Proc Natl Acad Sci U S A

    (1998)
  • A.R. Hipkiss et al.

    Carnosine and senescence

    Lifespan

    (1993)
  • A.A. Boldyrev et al.

    Carnosine: endogenous physiological corrector of antioxidative system activity

    Usp Fiziol Nauk

    (2007)
  • S. Gallant et al.

    Carnosine as a potential anti-senescence drug

    Biochemistry

    (2000)
  • M.Y. Kim et al.

    Effects of α-lipoic acid and l-carnosine supplementation on antioxidant activities and lipid profiles in rats

    Nutr Res Pract

    (2011)
  • B. Janssen et al.

    Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1

    Diabetes

    (2005)
  • I. Everaert et al.

    Low plasma carnosinase activity promotes carnosinemia after carnosine ingestion in humans

    Am J Physiol Renal Physiol

    (2012)
  • C.W. McDonough et al.

    The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans

    Hum Genet

    (2009)
  • Cited by (57)

    • Oxidative modification of HDL by lipid aldehydes impacts HDL function

      2022, Archives of Biochemistry and Biophysics
      Citation Excerpt :

      MESNA is used as an adjunctive treatment for chemotherapy [110–112], and experimentally for ulcerative colitis [113,114] and liver injury [115]. Carnosine, but not MESNA, also effectively scavenges MGO and carnosine has shown utility in treatment of diabetes [116,117], atherosclerosis [118,119], heart failure [120,121], and ischemic brain damage [122,123]. MESNA and carnosine are not effective for scavenging aldehydes that preferentially target primary amines like IsoLG.

    • Carnosine as a potential therapeutic for the management of peripheral vascular disease

      2022, Nutrition, Metabolism and Cardiovascular Diseases
      Citation Excerpt :

      Patients with PVD are also likely to have coronary heart disease, hypertension, metabolic syndrome, and kidney disease, however given the shared pathology, it is likely that carnosine will have a beneficial impact across the cardiovascular risk factor and disease spectrum. Indeed, it is known to have benefits in type 2 diabetes [12,45,48], renal disease [83], and heart failure [77], strengthening the case for its use in this population. While the preliminary evidence on the use of carnosine in PVD is supportive, however there is a critical lack of human studies in the field.

    • Histidine dipeptides are key regulators of excitation-contraction coupling in cardiac muscle: Evidence from a novel CARNS1 knockout rat model

      2021, Redox Biology
      Citation Excerpt :

      Our data, if replicated in humans, indicate that carnosine, anserine and their acetylated analogues could be promising therapeutic targets in cardiac diseases, especially because simple dietary interventions, can produce significant and consistent increases in their tissue content. While emerging evidence suggests that carnosine supplementation in patients with chronic heart failure can improve selected health outcomes [52], studies are still scarce, with high risk of bias [53] and lack proper mechanistic foundations. Advancing knowledge on the control of HCDs homeostasis in cardiac muscle is fundamental to develop effective nutritional therapies.

    View all citing articles on Scopus
    View full text